Trial Profile
The Maximum Tolerated Dose and Minimum Effective Dose of OROS Oxybutynin Compared to Ditropan (Immediate-Release Oxybutynin) in the Treatment of Patients With Urge or Mixed Urinary Incontinence
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Mixed incontinence; Urge incontinence
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 24 Nov 2006 New trial record.